Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53


RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML.

Brown AL, Arts P, Carmichael CL, Babic M, Dobbins J, Chong CE, Schreiber AW, Feng J, Phillips K, Wang PPS, Ha T, Homan CC, King-Smith SL, Rawlings L, Vakulin C, Dubowsky A, Burdett J, Moore S, McKavanagh G, Henry D, Wells A, Mercorella B, Nicola M, Suttle J, Wilkins E, Li XC, Michaud J, Brautigan P, Cannon P, Altree M, Jaensch L, Fine M, Butcher C, D'Andrea RJ, Lewis ID, Hiwase DK, Papaemmanuil E, Horwitz MS, Natsoulis G, Rienhoff HY, Patton N, Mapp S, Susman R, Morgan S, Cooney J, Currie M, Popat U, Bochtler T, Izraeli S, Bradstock K, Godley LA, Krämer A, Fröhling S, Wei AH, Forsyth C, Mar Fan H, Poplawski NK, Hahn CN, Scott HS.

Blood Adv. 2020 Mar 24;4(6):1131-1144. doi: 10.1182/bloodadvances.2019000901.


Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies.

Germing U, Oliva EN, Hiwase D, Almeida A.

Hemasphere. 2019 Oct 30;3(6):e314. doi: 10.1097/HS9.0000000000000314. eCollection 2019 Dec. Review.


Respiratory Viruses Cause Late Morbidity in Recipients of Hematopoietic Stem Cell Transplantation.

Marinelli T, Wee LYA, Rowe E, Chhetri R, Friel O, Higgins G, Bardy P, Singhal D, Pradhan A, Crawford L, Hiwase DK.

Biol Blood Marrow Transplant. 2019 Dec 20. pii: S1083-8791(19)31653-2. doi: 10.1016/j.bbmt.2019.12.724. [Epub ahead of print]


Cardiac and hepatic siderosis in myelodysplastic syndrome, thalassemia and diverse causes of transfusion-dependent anemia: the TIMES study.

Ho PJ, Hiwase D, Ramakrishna R, Viiala N, Solterbeck A, Traficante R, Zor E, Gervasio OL, High LM, Ross DM, Bowden DK.

Hemasphere. 2019 Jun 4;3(3):e224. doi: 10.1097/HS9.0000000000000224. eCollection 2019 Jun.


A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML.

Schwarer AP, Butler J, Jackson K, Beligaswatte A, Martin L, Kennedy G, Daniela Z, Lewis I, Hiwase D, Wight J, He S, Grigg A, Morris K, Mollee P, Marlton P.

Hemasphere. 2018 Nov 28;2(6):e158. doi: 10.1097/HS9.0000000000000158. eCollection 2018 Dec.


Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis.

Brown AL, Hahn C, Hiwase D, Godley LA, Scott HS.

Leuk Lymphoma. 2020 Jan;61(1):246-247. doi: 10.1080/10428194.2019.1680842. Epub 2019 Oct 24. No abstract available.


Clinical Effectiveness of Conjugate Pneumococcal Vaccination in Hematopoietic Stem Cell Transplantation Recipients.

Roberts MB, Bak N, Wee LYA, Chhetri R, Yeung DT, Lewis I, Hiwase DK.

Biol Blood Marrow Transplant. 2020 Feb;26(2):421-427. doi: 10.1016/j.bbmt.2019.10.006. Epub 2019 Oct 15.


Genomics of therapy-related myeloid neoplasms.

Kuzmanovic T, Patel BJ, Sanikommu SR, Nagata Y, Awada H, Kerr CM, Przychodzen BP, Jha BK, Hiwase D, Singhal D, Advani AS, Nazha A, Gerds AT, Carraway HE, Sekeres MA, Mukherjee S, Maciejewski JP, Radivoyevitch T.

Haematologica. 2020 Mar;105(3):e98-e101. doi: 10.3324/haematol.2019.219352. Epub 2019 Aug 14. No abstract available.


The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution.

Singhal D, Wee LYA, Kutyna MM, Chhetri R, Geoghegan J, Schreiber AW, Feng J, Wang PP, Babic M, Parker WT, Hiwase S, Edwards S, Moore S, Branford S, Kuzmanovic T, Singhal N, Gowda R, Brown AL, Arts P, To LB, Bardy PG, Lewis ID, D'Andrea RJ, Maciejewski JP, Scott HS, Hahn CN, Hiwase DK.

Leukemia. 2019 Dec;33(12):2842-2853. doi: 10.1038/s41375-019-0479-8. Epub 2019 May 14.


Screening for deficits using the G8 and VES-13 in older patients with Myelodysplastic syndromes.

Molga A, Wall M, Wee LYA, Chhetri R, Singhal D, Singhal N, To LB, Shakib S, To T, Hiwase D.

J Geriatr Oncol. 2020 Jan;11(1):128-130. doi: 10.1016/j.jgo.2019.04.012. Epub 2019 May 1. No abstract available.


Comprehensive geriatric assessment predicts azacitidine treatment duration and survival in older patients with myelodysplastic syndromes.

Molga A, Wall M, Chhetri R, Wee LY, Singhal D, Edwards S, Singhal N, Ross D, To LB, Caughey G, Shakib S, Germing U, To T, Hiwase D.

J Geriatr Oncol. 2020 Jan;11(1):114-120. doi: 10.1016/j.jgo.2019.02.002. Epub 2019 Apr 22.


Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission.

Shanmuganathan N, Braley JA, Yong ASM, Hiwase DK, Yeung DT, Ross DM, Hughes TP, Branford S.

Blood. 2019 Jul 4;134(1):85-89. doi: 10.1182/blood.2019000120. Epub 2019 Apr 9. No abstract available.


Red cell autoimmunization and alloimmunization in myelodysplastic syndromes: prevalence, characteristic and significance.

Chhetri R, Wee LYA, Sinha R, Kutyna MM, Pham A, Stathopoulos H, Nath L, Nath SV, Wickham N, Hughes T, Singhal D, Roxby DJ, Hiwase DK.

Haematologica. 2019 Oct;104(10):e451-e454. doi: 10.3324/haematol.2018.215087. Epub 2019 Feb 28. No abstract available.


Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI.

Shanmuganathan N, Branford S, Hughes TP, Hiwase D.

Blood Adv. 2019 Feb 12;3(3):370-374. doi: 10.1182/bloodadvances.2018027516. No abstract available.


Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia.

Kenealy M, Hertzberg M, Benson W, Taylor K, Cunningham I, Stevenson W, Hiwase D, Eek R, Zantomio D, Jong S, Wall M, Blombery P, Gerber T, Debrincat M, Zannino D, Seymour JF.

Haematologica. 2019 Apr;104(4):700-709. doi: 10.3324/haematol.2018.201152. Epub 2018 Dec 13.


Revisiting acquired aplastic anaemia: current concepts in diagnosis and management.

Clucas DB, Fox LC, Wood EM, Hong FS, Gibson J, Bajel A, Szer J, Blombery P, McQuilten ZK, Hiwase D, Firkin F, Cole-Sinclair MF; Australian Aplastic Anaemia Registry Steering Committee.

Intern Med J. 2019 Feb;49(2):152-159. doi: 10.1111/imj.14140. Review.


Inflammatory myopathies after allogeneic stem cell transplantation.

New-Tolley J, Smith C, Koszyca B, Otto S, Maundrell A, Bardy P, Hiwase D, Yong ASM, Lewis I, Limaye V.

Muscle Nerve. 2018 Dec;58(6):790-795. doi: 10.1002/mus.26341. Epub 2018 Nov 20.


Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.

Hiwase D, Tan P, D'Rozario J, Taper J, Powell A, Irving I, Wright M, Branford S, Yeung DT, Anderson L, Gervasio O, Levetan C, Roberts W, Solterbeck A, Traficante R, Hughes T.

Leuk Res. 2018 Apr;67:109-115. doi: 10.1016/j.leukres.2018.02.013. Epub 2018 Feb 21.


Success is built on failures: tackling the challenge of ponatinib failure.

Hiwase D, Ross D.

Leuk Lymphoma. 2018 Jun;59(6):1279-1281. doi: 10.1080/10428194.2018.1427864. Epub 2018 Jan 31. No abstract available.


Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome.

Singhal D, Kutyna MM, Chhetri R, Wee LYA, Hague S, Nath L, Nath SV, Sinha R, Wickham N, Lewis ID, Ross DM, Bardy PG, To LB, Reynolds J, Wood EM, Roxby DJ, Hiwase DK.

Haematologica. 2017 Dec;102(12):2021-2029. doi: 10.3324/haematol.2017.175752. Epub 2017 Oct 5.


Myeloid neoplasms with germline DDX41 mutation.

Cheah JJC, Hahn CN, Hiwase DK, Scott HS, Brown AL.

Int J Hematol. 2017 Aug;106(2):163-174. doi: 10.1007/s12185-017-2260-y. Epub 2017 May 25. Review.


Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome.

Shanmuganathan N, Hiwase DK, Ross DM.

Leuk Lymphoma. 2017 Dec;58(12):2799-2810. doi: 10.1080/10428194.2017.1312377. Epub 2017 May 9. Review.


The only thing that is constant is change: The 2016 revision to the World Health Organisation classification of myelodysplastic syndrome.

Hiwase D.

Leuk Res. 2017 Jun;57:102-103. doi: 10.1016/j.leukres.2017.02.013. Epub 2017 Mar 6. No abstract available.


Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients.

Hiwase DK, Singhal D, Strupp C, Chhetri R, Kutyna MM, Wee LA, Harrison PB, Nath SV, Wickham N, Hui CH, Gray JX, Bardy P, Ross DM, Lewis ID, Reynolds J, To LB, Germing U.

Am J Hematol. 2017 Jun;92(6):508-514. doi: 10.1002/ajh.24704. Epub 2017 Mar 20.


Impaired haematopoietic stem cell differentiation and enhanced skewing towards myeloid progenitors in aged caspase-2-deficient mice.

Dawar S, Shahrin NH, Sladojevic N, D'Andrea RJ, Dorstyn L, Hiwase DK, Kumar S.

Cell Death Dis. 2016 Dec 1;7(12):e2509. doi: 10.1038/cddis.2016.406.


TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy.

Nievergall E, Reynolds J, Kok CH, Watkins DB, Biondo M, Busfield SJ, Vairo G, Fuller K, Erber WN, Sadras T, Grose R, Yeung DT, Lopez AF, Hiwase DK, Hughes TP, White DL.

Leukemia. 2016 Jun;30(6):1263-72. doi: 10.1038/leu.2016.34. Epub 2016 Feb 22.


A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone.

Hahn CN, Ross DM, Feng J, Beligaswatte A, Hiwase DK, Parker WT, Ho M, Zawitkowski M, Ambler KL, Cheetham GD, Lee YK, Babic M, Butcher CM, Engler GA, Brown AL, D'Andrea RJ, Lewis ID, Schreiber AW, To LB, Scott HS.

Leukemia. 2015 Oct;29(10):2101-4. doi: 10.1038/leu.2015.67. Epub 2015 Mar 9. No abstract available.


TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.

Yeung DT, Osborn MP, White DL, Branford S, Braley J, Herschtal A, Kornhauser M, Issa S, Hiwase DK, Hertzberg M, Schwarer AP, Filshie R, Arthur CK, Kwan YL, Trotman J, Forsyth CJ, Taper J, Ross DM, Beresford J, Tam C, Mills AK, Grigg AP, Hughes TP; Australasian Leukaemia and Lymphoma Group.

Blood. 2015 Feb 5;125(6):915-23. doi: 10.1182/blood-2014-07-590315. Epub 2014 Dec 17.


Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy.

Hahn CN, Venugopal P, Scott HS, Hiwase DK.

Immunol Rev. 2015 Jan;263(1):257-78. doi: 10.1111/imr.12241. Review.


Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia.

Schafranek L, Nievergall E, Powell JA, Hiwase DK, Leclercq T, Hughes TP, White DL.

Leukemia. 2015 Jan;29(1):76-85. doi: 10.1038/leu.2014.156. Epub 2014 May 12.


Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells.

Nievergall E, Ramshaw HS, Yong AS, Biondo M, Busfield SJ, Vairo G, Lopez AF, Hughes TP, White DL, Hiwase DK.

Blood. 2014 Feb 20;123(8):1218-28. doi: 10.1182/blood-2012-12-475194. Epub 2013 Dec 20.


Loss of caspase-2 augments lymphomagenesis and enhances genomic instability in Atm-deficient mice.

Puccini J, Shalini S, Voss AK, Gatei M, Wilson CH, Hiwase DK, Lavin MF, Dorstyn L, Kumar S.

Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):19920-5. doi: 10.1073/pnas.1311947110. Epub 2013 Nov 18.


Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells.

White DL, Eadie LN, Saunders VA, Hiwase DK, Hughes TP.

Leukemia. 2013 Apr;27(5):1201-4. doi: 10.1038/leu.2012.295. Epub 2012 Oct 16. No abstract available.


Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells.

Hiwase DK, Saunders VA, Nievergall E, Ross DD, White DL, Hughes TP.

Haematologica. 2013 Jun;98(6):896-900. doi: 10.3324/haematol.2012.070268. Epub 2012 Oct 12.


Relapsed multiple myeloma: who benefits from salvage autografts?

Chow AW, Lee CH, Hiwase DK, To LB, Horvath N.

Intern Med J. 2013 Feb;43(2):156-61. doi: 10.1111/j.1445-5994.2012.02867.x.


Sudden blast crisis in chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Hiwase DK, Hughes TP.

Leuk Lymphoma. 2012 Jul;53(7):1251-2. doi: 10.3109/10428194.2012.682314. Epub 2012 Apr 23. No abstract available.


Mobilisation strategies for normal and malignant cells.

To LB, Levesque JP, Herbert KE, Winkler IG, Bendall LJ, Hiwase DK, Antonenas V, Rice AM, Gottlieb D, Mills AK, Rasko JE, Larsen S, Beligaswatte A, Nilsson SK, Cooney JP, Cambareri AC, Lewis ID.

Pathology. 2011 Oct;43(6):547-65. doi: 10.1097/PAT.0b013e32834a9eb8. Review.


Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients.

Hiwase DK, Yeung DT, White DL.

Expert Rev Hematol. 2011 Jun;4(3):285-99. doi: 10.1586/ehm.11.19. Review.


Ndfip1-deficient mice have impaired DMT1 regulation and iron homeostasis.

Foot NJ, Leong YA, Dorstyn LE, Dalton HE, Ho K, Zhao L, Garrick MD, Yang B, Hiwase D, Kumar S.

Blood. 2011 Jan 13;117(2):638-46. doi: 10.1182/blood-2010-07-295287. Epub 2010 Oct 19.


Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors.

Hiwase DK, White DL, Powell JA, Saunders VA, Zrim SA, Frede AK, Guthridge MA, Lopez AF, D'Andrea RJ, To LB, Melo JV, Kumar S, Hughes TP.

Leukemia. 2010 Apr;24(4):771-8. doi: 10.1038/leu.2009.299. Epub 2010 Feb 4.


Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy.

Hiwase DK, White D, Zrim S, Saunders V, Melo JV, Hughes TP.

Leukemia. 2010 Mar;24(3):658-60. doi: 10.1038/leu.2009.242. Epub 2009 Dec 10. No abstract available.


Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL(+) cells.

Hiwase DK, White DL, Saunders VA, Kumar S, Melo JV, Hughes TP.

Leukemia. 2009 Jun;23(6):1205-6. doi: 10.1038/leu.2009.45. Epub 2009 Mar 5. No abstract available.


The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma.

Hiwase DK, Hiwase S, Bailey M, Bollard G, Schwarer AP.

Cytotherapy. 2008;10(5):507-17. doi: 10.1080/14653240802165665.


Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.

Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, Dang P, Eadie L, To LB, Melo J, Kumar S, Hughes TP, White DL.

Clin Cancer Res. 2008 Jun 15;14(12):3881-8. doi: 10.1158/1078-0432.CCR-07-5095.


Autoimmune haemolytic anaemia as the presenting manifestation of agnogenic myeloid metaplasia.

Mohite U, Pathare A, al Kindi S, Hiwase D, Vadakkepat N, Knox-Macaulay H.

Haematologia (Budap). 2002;32(4):495-9.


Pseudotumour cerebri occurring before treatment of acute promyelocytic leukaemia with all-trans-retinoic acid (ATRA).

Knox-Macaulay HH, Hiwase D, Nusrat N, Ganesh A.

Haematologia (Budap). 2002;32(1):81-5. No abstract available.


Acute myelomonocytic leukaemia with pseudo-Chediak-Higashi inclusions in leukaemic blasts report of an unusual case.

Ghosh K, Khanduri U, Hiwase D, Venugopal S, Muirhead D.

Haematologia (Budap). 2000;30(3):229-34.


Primary pseudomonas meningitis in an adult, splenectomized, multitransfused thalassaemia major patient.

Ghosh K, Daar S, Hiwase D, Nursat N.

Haematologia (Budap). 2000;30(1):69-72.


Supplemental Content

Loading ...
Support Center